0.4687
Schlusskurs vom Vortag:
$0.4436
Offen:
$0.4436
24-Stunden-Volumen:
785.89K
Relative Volume:
1.68
Marktkapitalisierung:
$22.69M
Einnahmen:
$1.14M
Nettoeinkommen (Verlust:
$-60.82M
KGV:
-0.3514
EPS:
-1.3338
Netto-Cashflow:
$-60.29M
1W Leistung:
+7.66%
1M Leistung:
-43.27%
6M Leistung:
-52.79%
1J Leistung:
-59.90%
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Firmenname
Werewolf Therapeutics Inc
Sektor
Branche
Telefon
617-952-0555
Adresse
200 TALCOTT AVENUE, WATERTOWN
Compare HOWL vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
HOWL
Werewolf Therapeutics Inc
|
0.4669 | 21.56M | 1.14M | -60.82M | -60.29M | -1.3338 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-19 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-04-03 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-08-24 | Eingeleitet | Wedbush | Outperform |
| 2023-06-06 | Fortgesetzt | Jefferies | Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-05-25 | Eingeleitet | Evercore ISI | Outperform |
| 2021-05-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-25 | Eingeleitet | Jefferies | Buy |
| 2021-05-25 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Werewolf Therapeutics Inc Aktie (HOWL) Neueste Nachrichten
HOWL Q1 2026 Earnings: Narrowed Loss Exceeds Estimates, Stock RisesProfit Announcement - Newser
HOWL Stock Chart | WEREWOLF THERAPEUTICS INC (NASDAQ:HOWL) - ChartMill
Werewolf Therapeutics (HOWL) Stock Price, News & Analysis - MarketBeat
Werewolf Therapeutics director Luke Evnin sells $76,363 in stock - Investing.com
Evnin-linked funds sell 171K Werewolf Therapeutics (HOWL) shares - Stock Titan
[144] Werewolf Therapeutics, Inc. SEC Filing - Stock Titan
Werewolf Therapeutics Stock Rises Over 5% After Hours On Workforce Reduction, Including Executives - Stocktwits
Werewolf Therapeutics (HOWL) Stock: Down -3.84%, Support Test at $0.47 2026-05-18ATR Levels - newser.com
Werewolf Therapeutics (HOWL) price target increased by 12.00% to 7.14 - MSN
Werewolf Therapeutics (HOWL) price target increased by 20.19% to 6.38 - MSN
Should You Sell Werewolf Therapeutics (HOWL) After -5.07% Drop? 2026-05-17Head and Shoulders - Newser
Werewolf Therapeutics (HOWL) Reports Strong Q4 2025 — Revenue $N/A, EPS BeatsCommunity Watchlist - Newser
RA Capital funds sell HOWL shares, report 12.6% Werewolf Therapeutics stake - Stock Titan
News | Struggling Boston biotech firm cuts ties with headquarters space - CoStar
Werewolf Therapeutics Insider Sold Shares Worth $280,210, According to a Recent SEC Filing - Moomoo
Here's Why We're A Bit Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Situation - Yahoo Finance
HOWL Director Luke Evnin Sells 44,679 Shares on May 13, 2026 - Meyka
Werewolf Therapeutics director Luke Evnin sells $24,126 in stock - Investing.com UK
Werewolf Therapeutics director Luke Evnin sells $24,126 in stock By Investing.com - Investing.com Australia
Evnin-linked funds sell 44,679 Werewolf (NASDAQ: HOWL) shares under plan - Stock Titan
Werewolf Therapeutics vacates Watertown headquarters as cash dwindles - The Business Journals
TradingKey - TradingKey
Werewolf Therapeutics director Luke Evnin sells $280,210 in company stock By Investing.com - Investing.com South Africa
Werewolf Therapeutics director Luke Evnin sells $280,210 in company stock - Investing.com India
MPM group cuts Werewolf Therapeutics (HOWL) holdings in May stock sales - Stock Titan
Director-linked MPM funds trim Werewolf Therapeutics (HOWL) stake under 10b5-1 plan - Stock Titan
Ra capital, Peter Kolchinsky sell $390k Werewolf Therapeutics shares - Investing.com India
Ra capital, Peter Kolchinsky sell $390k Werewolf Therapeutics shares By Investing.com - Investing.com South Africa
RA Capital funds trim Werewolf Therapeutics (NASDAQ: HOWL) stake with 565K-share sale - Stock Titan
HOWL SEC FilingsWerewolf Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
B of A Securities Maintains Werewolf Therapeutics (HOWL) Buy Recommendation - MSN
Werewolf sells JZP898 rights to Jazz, repays K2 debt amid review - Stock Titan
Werewolf Therapeutics (NASDAQ:HOWL) Meets Q1 Estimates, Clears Debt, and Advances Strategic Review - ChartMill
Werewolf Therapeutics director Luke Evnin sells $64,216 in shares - Investing.com UK
Werewolf Therapeutics director Luke Evnin sells $64,216 in shares By Investing.com - Investing.com Nigeria
Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates - Investing News Network
Funds tied to Werewolf Therapeutics (HOWL) director sell 100,581 shares - Stock Titan
Werewolf Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Strategic review, Jazz asset sale and Q1 loss at Werewolf Therapeutics (NASDAQ: HOWL) - Stock Titan
[10-Q] Werewolf Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Finanzdaten der Werewolf Therapeutics Inc-Aktie (HOWL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Werewolf Therapeutics Inc-Aktie (HOWL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| EVNIN LUKE | Director |
May 19 '26 |
Sale |
0.45 |
62,970 |
28,336 |
1,041,342 |
| EVNIN LUKE | Director |
May 18 '26 |
Sale |
0.50 |
22,184 |
11,092 |
1,104,312 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):